[Therapy monitoring in cardiac arrhythmias: guidelines for evaluation of anti-arrhythmia effects]. / Therapiekontrolle bei Herzrhythmusstörungen: Richtlinien zur Prüfung antiarrhythmischer Wirkungen.

ABSTRACT

The incidence of avoidable or unavoidable, cardial and extracardial side effects is a risk in the drug treatment of supraventricular and ventricular tachyarrhythmias. Therefore the indication of antiarrhythmic drug therapy has to be considered critically. The patient has to be controlled close-meshed, especially at the beginning of the drug treatment. In patients with life threatening ventricular tachyarrhythmias, which can not be suppressed by drug therapy, nonpharmacological therapy--implantable cardioverter/defibrillator, catheterablation and heart-transplantation--has to be discussed.